Table 2.
Hazard ratio (HR) and 95% confidence interval (95% CI) for 5-years disease-free survival (DFS) in the FL + OXA (n = 151), FL (n = 119), and pooled (n = 270) cohorts of stages II–III colorectal patients according to gene polymorphisms (SNPs).
| Gene | SNP | Base change | FL + OXA (n = 151) | FL (n = 119) | ||||
|---|---|---|---|---|---|---|---|---|
| Mod | HR (95% CI)a | p-value | q-valueb | HR (95% CI)a | p-value | |||
| SMAD3 | rs11636161 | G > A | Rec | 2.81 (1.38–5.71) | 0.004 | 0.108 | 1.67 (0.81–3.45) | 0.168 |
| SMAD3 | rs1545161 | A > G | Add | 0.53 (0.33–0.85) | 0.008 | 0.185 | 1.03 (0.65–1.64) | 0.892 |
| FOXO3 | rs12203787 | G > C | Dom | 0.33 (0.13–0.86) | 0.024 | 0.203 | 1.37 (0.52–3.64) | 0.522 |
| IFNG | rs1861494 | A > G | Dom | 2.14 (1.13–4.08) | 0.020 | 0.249 | 1.97 (1.00–3.86) | 0.049 |
| VEGFA | rs2146323 | C > A | Dom | 0.43 (0.22–0.84) | 0.014 | 0.203 | 0.86 (0.41–1.80) | 0.688 |
| TGFBR1 | rs928180 | A > G | Dom | 2.40 (1.21–4.75) | 0.012 | 0.194 | 1.63 (0.61–4.40) | 0.333 |
| TGFBR2 | rs1346907 | A > G | Rec | 2.49 (1.24–4.98) | 0.010 | 0.194 | 0.57 (0.18–1.77) | 0.329 |
| STAT5A | rs7217728 | A > G | Rec | 3.58 (1.71–7.48) | 0.001 | 0.032 | 0.58 (0.17–2.06) | 0.404 |
| STAT5B | rs8080122 | G > A | Rec | 4.57 (1.9–10.99) | 0.001 | 0.032 | 0.58 (0.17–2.06) | 0.402 |
95% CI, 95% confidence interval; FL, fluoropyrimidines; HR, hazard ratio; OXA, oxaliplatin; SNP, single nucleotide polymorphism. aEstimated from Cox model, adjusted for gender, age, cancer site, stage at diagnosis. bFalse discovery rate-adjusted p-value. Only the associations with P < 0.05 are reported in the FL + OXA set and replicated in the FL cohort. Markers with the same predictive effect and below the cut-off for statistical significance (P < 0.05) in all cohorts are evidenced in bold.